GB202005114D0 - Crystalline Forms of a Pharmaceutical Compound - Google Patents
Crystalline Forms of a Pharmaceutical CompoundInfo
- Publication number
- GB202005114D0 GB202005114D0 GBGB2005114.0A GB202005114A GB202005114D0 GB 202005114 D0 GB202005114 D0 GB 202005114D0 GB 202005114 A GB202005114 A GB 202005114A GB 202005114 D0 GB202005114 D0 GB 202005114D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- crystalline forms
- pharmaceutical compound
- pharmaceutical
- compound
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005114.0A GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
| JP2022559959A JP7660135B2 (ja) | 2020-04-07 | 2021-04-06 | Tyk2阻害剤の結晶形態 |
| IL296989A IL296989A (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
| US17/905,183 US12545652B2 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a TYK2 inhibitor |
| PCT/EP2021/058864 WO2021204762A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
| BR112022016359A BR112022016359A2 (pt) | 2020-04-07 | 2021-04-06 | Formas cristalinas de um composto farmacêutico |
| CA3167172A CA3167172A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
| AU2021253128A AU2021253128B2 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a TYK2 inhibitor |
| MX2022011593A MX2022011593A (es) | 2020-04-07 | 2021-04-06 | Formas cristalinas de un compuesto farmaceutico. |
| EP21717041.4A EP4132649A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
| CN202180025999.3A CN115515683B (zh) | 2020-04-07 | 2021-04-06 | Tyk2抑制剂的晶型 |
| KR1020227038120A KR20220164751A (ko) | 2020-04-07 | 2021-04-06 | Tyk2 억제제의 결정질 형태 |
| US19/440,870 US20260217664A1 (en) | 2020-04-07 | 2026-01-06 | Crystalline forms of a tyk2 inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005114.0A GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202005114D0 true GB202005114D0 (en) | 2020-05-20 |
Family
ID=70768933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2005114.0A Ceased GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12545652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132649A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7660135B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220164751A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515683B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022016359A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167172A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202005114D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296989A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011593A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021204762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| JP2025510826A (ja) * | 2022-03-25 | 2025-04-15 | 武田薬品工業株式会社 | Tyk2阻害剤の固体形態及び使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| BR0111754A (pt) | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| AU2479702A (en) | 2000-10-30 | 2002-05-15 | Janssen Pharmaceutica Nv | Tripeptidyl peptidase inhibitors |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| ATE465731T1 (de) | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8367706B2 (en) | 2007-06-20 | 2013-02-05 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2310384B1 (en) | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| ES2566205T3 (es) | 2012-03-02 | 2016-04-11 | Sareum Limited | Inhibidores de quinasa TYK2 |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| BR112016004723B1 (pt) * | 2013-09-03 | 2022-08-30 | Sareum Limited | Compostos de pirrolidina ou morfolina e composição contendo os mesmos |
| NO2721710T3 (cg-RX-API-DMAC7.html) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
-
2020
- 2020-04-07 GB GBGB2005114.0A patent/GB202005114D0/en not_active Ceased
-
2021
- 2021-04-06 IL IL296989A patent/IL296989A/en unknown
- 2021-04-06 BR BR112022016359A patent/BR112022016359A2/pt unknown
- 2021-04-06 MX MX2022011593A patent/MX2022011593A/es unknown
- 2021-04-06 WO PCT/EP2021/058864 patent/WO2021204762A1/en not_active Ceased
- 2021-04-06 JP JP2022559959A patent/JP7660135B2/ja active Active
- 2021-04-06 EP EP21717041.4A patent/EP4132649A1/en active Pending
- 2021-04-06 US US17/905,183 patent/US12545652B2/en active Active
- 2021-04-06 CN CN202180025999.3A patent/CN115515683B/zh active Active
- 2021-04-06 KR KR1020227038120A patent/KR20220164751A/ko active Pending
- 2021-04-06 CA CA3167172A patent/CA3167172A1/en active Pending
-
2026
- 2026-01-06 US US19/440,870 patent/US20260217664A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021253128A1 (en) | 2022-08-25 |
| KR20220164751A (ko) | 2022-12-13 |
| JP7660135B2 (ja) | 2025-04-10 |
| EP4132649A1 (en) | 2023-02-15 |
| MX2022011593A (es) | 2022-10-18 |
| CA3167172A1 (en) | 2021-10-14 |
| US20230159473A1 (en) | 2023-05-25 |
| IL296989A (en) | 2022-12-01 |
| BR112022016359A2 (pt) | 2022-10-04 |
| CN115515683A (zh) | 2022-12-23 |
| WO2021204762A1 (en) | 2021-10-14 |
| CN115515683B (zh) | 2024-10-25 |
| US20260217664A1 (en) | 2026-07-30 |
| US12545652B2 (en) | 2026-02-10 |
| JP2023521631A (ja) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065214T3 (en) | Crystalline forms of a btk inhibitor | |
| IL316075A (en) | Crystalline form of lenifranor | |
| DK4114826T3 (da) | Krystallinske former af en farmaceutisk forbindelse | |
| IL304497A (en) | Crystalline forms of a pyrrolopyridine-aniline compound | |
| AU2021400317A9 (en) | Solid forms of a compound | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| IL321053A (en) | Crystalline forms of HER2 inhibitor | |
| GB202102360D0 (en) | Crystalline compound | |
| EP3923948A4 (en) | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR | |
| IL288547A (en) | Salts of non-hygroscopic crystalline pyrazole compound, pharmaceutical preparations thereof and use thereof | |
| IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
| EP3927707A4 (en) | SOLID POLYMORPHS OF A FLIN-BINDING COMPOUND AND ITS HYDROCHLORIDE SALTS | |
| GB2593902B (en) | Salt of a pharmaceutical compound | |
| IL304683A (en) | Crystalline form of a piperazinyl-thiazole derivative | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| GB202301180D0 (en) | Salt of a pharmaceutical compound | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| GB202213819D0 (en) | Pharmaceutical compound | |
| IL292206A (en) | The salts of a compound and its crystalline forms | |
| HK40104193A (en) | Crystalline form of a piperazinyl-thiazole derivative | |
| HK40099801A (en) | Solid forms of a compound | |
| GB202217726D0 (en) | Crystalline compound | |
| PL4347565T3 (pl) | Otrzymywanie związku inhibitora chk1 | |
| HK40086278A (en) | Crystalline forms of a tyk2 inhibitor | |
| GB202217888D0 (en) | Pharmaceutical compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |